Related Experiment Videos
Piperacillin/tazobactam in complicated urinary tract infections
1Department of Urology, Algemeen Ziekenhuis Middelheim, Antwerp, Belgium.
Abstract:
Piperacillin/tazobactam, at a dosage of 4 g/500 mg every 8 h, was administered intravenously to 217 patients with complicated urinary tract infections. The most common diagnosis was pyelonephritis. The most common pathogen was Escherichia coli (47%) followed by Pseudomonas aeruginosa (13%), and enterococci (8%). Among clinically evaluable patients, 86% (115/134) were cured or improved at the study endpoint and 14% (19/134) were clinical failures or relapsed. Among bacteriologically evaluable patients, 85% (95/112) had a favorable clinical response at endpoint. The bacteriological response rate was 73% (82/112) at endpoint. Overall, 82% of all pathogens were eradicated. Therapy was associated with a low incidence of side effects, and adverse experience were mild and of short duration.
Insights
Piperacillin/tazobactam effectively treated complicated urinary tract infections in 217 patients, showing high cure rates and pathogen eradication. Adverse effects were mild and infrequent, indicating a favorable safety profile for this antibiotic combination.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Complicated urinary tract infections (cUTIs) pose a significant clinical challenge.
- Prompt and effective antimicrobial therapy is crucial for managing cUTIs and preventing complications.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin/tazobactam in patients with complicated urinary tract infections.
- To assess clinical and bacteriological response rates and pathogen eradication.
- To determine the incidence of adverse events associated with the treatment.
Main Methods:
- A prospective study involving 217 patients with complicated urinary tract infections.
- Intravenous administration of piperacillin/tazobactam at a dosage of 4 g/500 mg every 8 hours.
- Evaluation of clinical cure/improvement, clinical failure/relapse, and bacteriological response at study endpoint.
Main Results:
- 86% of clinically evaluable patients achieved cure or improvement.
- 85% of bacteriologically evaluable patients had a favorable clinical response.
- 82% of all identified pathogens were eradicated.
- Adverse experiences were mild and of short duration, with a low incidence.
Conclusions:
- Piperacillin/tazobactam demonstrates high efficacy in treating complicated urinary tract infections, including pyelonephritis.
- The treatment regimen is well-tolerated, with a favorable safety profile.
- Effective eradication of common pathogens like Escherichia coli and Pseudomonas aeruginosa was observed.